University of Tennessee Research Foundation;Gtx; Inc.;Gtx, Inc.
发明人:
NARAYANAN, Ramesh,MILLER, Duane D.,PONNUSAMY, Thamarai,HWANG, Dong-Jin,DUKE, Charles B.,COSS, Christopher C.,JONES, Amanda,DALTON, James T.
申请号:
EP16783846
公开号:
EP3285757A4
申请日:
2016.04.21
申请国别(地区):
EP
年份:
2018
代理人:
摘要:
This invention provides novel 3-amino propanamide selective androgen receptor degrader (SARD) compounds, pharmaceutical compositions and uses thereof in treating prostate cancer, advanced prostate cancer, castration resistant prostate cancer, androgenic alopecia or other hyperandrogenic dermal diseases, Kennedy's disease, amyotrophic lateral sclerosis (ALS), and uterine fibroids, and to methods for reducing the levels of androgen receptor-full length (AR-FL) including pathogenic or resistance mutations, AR-splice variants (AR-SV), and pathogenic polyglutamine (polyQ) polymorphisms of AR in a subject.